Specialty pharma company US WorldMeds said today that an FDA committee voted 11-1 to recommend approval for lofexidine, a selective alpha 2-adrenergic receptor agonist designed to mitigate the symptoms of opioid withdrawal. The oral drug, which US WorldMeds intends to market under the name Lucemyra, reduces the release of norepinephrine in a person’s brain and suppresses […]